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Abstract
Background and Aims: Recent studies indicate that hepatitis C virus (HCV) can modulate the expression of various genes
including those involved in interferon signaling, and up-regulation of interferon-stimulated genes by HCV was reported to
be strongly associated with treatment outcome. To expand our understanding of the molecular mechanism underlying
treatment resistance, we analyzed the direct effects of interferon and/or HCV infection under immunodeficient conditions
using cDNA microarray analysis of human hepatocyte chimeric mice.
Methods: Human serum containing HCV genotype 1b was injected into human hepatocyte chimeric mice. IFN-a was
administered 8 weeks after inoculation, and 6 hours later human hepatocytes in the mouse livers were collected for
microarray analysis.
Results: HCV infection induced a more than 3-fold change in the expression of 181 genes, especially genes related to
Organismal Injury and Abnormalities, such as fibrosis or injury of the liver (P=5.90E-16 , 3.66E-03). IFN administration
induced more than 3-fold up-regulation in the expression of 152 genes. Marked induction was observed in the anti-fibrotic
chemokines such as CXCL9, suggesting that IFN treatment might lead not only to HCV eradication but also prevention and
repair of liver fibrosis. HCV infection appeared to suppress interferon signaling via significant reduction in interferon-
induced gene expression in several genes of the IFN signaling pathway, including Mx1, STAT1, and several members of the
CXCL and IFI families (P=6.0E-12). Genes associated with Antimicrobial Response and Inflammatory Response were also
significantly repressed (P=5.22610
210 , 1.95610
22).
Conclusions: These results provide molecular insights into possible mechanisms used by HCV to evade innate immune
responses, as well as novel therapeutic targets and a potential new indication for interferon therapy.
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Introduction
Chronic hepatitis C virus (HCV) infection is one of the most
serious global health threats, affecting more than 170 million
people worldwide [1–3]. Interferon is administered to chronic
hepatitis C patients to attempt to eradicate the virus and to
prevent the development of advanced liver diseases such as
chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC),
with limited success. While the overall eradication rate of HCV
has improved since the introduction of pegylated-interferon (PEG-
IFN) and ribavirin (RBV) combination therapy, the sustained viral
response (SVR) rate of genotype 1b with high viral load still
remains only 40–50% [4–6]. Viral and host factors, such as HCV
RNA titer, viral substitutions in HCV core or NS5A region, age,
gender, liver fibrosis, and SNPs in IL-28B locus, are significantly
associated with the effects of PEG-IFN and RBV combination
therapy [7–15], but the precise molecular mechanisms remained
unclear.
Recently, some HCV-related structural as well as non-structural
proteins have been reported to be associated with host proteins
and affect innate immunity or lipid metabolism. RIG-I (retinoic
acid inducible gene I) and Mda5 (melanoma differentiation-
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signaling pathway by interacting with adaptor protein IPS-1/
MAVS/VISA/Cardif [16–18]. In the presence of HCV infection,
the viral non-structural protein NS3/4A, which has serine
protease activity, can cleave and inactivate IPS-1 [19]. TLR (Toll
like receptor) is a sensor of RNA or DNA and is known to play
various roles in viral infection. Abe et al. demonstrated that HCV
non-structural protein NS5A inhibits the recruitment of interleu-
kin-1 receptor-associated kinase 1 by interacting with MyD88 and
impairs cytokine production in response to TLR ligands [20].
HCV core protein is also known to interact with host proteins. The
core protein promotes hepatic steatosis, insulin resistance and
hepatocarcinogenesis through activation of host proteins such as
PPARa and MAPK [21–26]. However, these reports were based
on in vitro analysis of cell lines or used human liver tissues in which
results were complicated by adaptive immune responses, and it has
been difficult to evaluate the direct impact of HCV infection and
interferon administration on human hepatocytes.
Mercer and colleagues developed a human hepatocyte chimeric
mouse [27] derived from the severely immunocompromised SCID
mouse, in which mouse liver cells were extensively replaced with
human hepatocytes [27,28]. This mouse model facilitates
continuous HCV infection and makes it possible to analyze the
effects of drugs and viral infection on human hepatocytes under
immunodeficient conditions [29,30]. To analyze the putative
effects of HCV infection or IFN administration without the
adaptive immune response, we constructed an HCV carrier mouse
model using the human hepatocyte chimeric mouse and
performed cDNA microarray analysis using human hepatocytes
dissected from the mouse livers. The results are intended to reflect
the direct impacts of HCV infection and IFN administration on
human hepatocytes and may help in elucidating HCV immune
evasion mechanisms.
Materials and Methods
Human Serum Samples
Serum samples were obtained from HCV carriers after
obtaining written informed consent for the donation and
evaluation of blood samples. Inocula contained high viral loads
of genotype 1b HCV RNA (6.9 log copies/ml). The experimental
protocol met the ethical guidelines of the 1975 Declaration of
Helsinki and was approved by the Hiroshima University Ethical
Committee.
Human Hepatocyte Chimeric Mice Experiments
The uPA
+/+/SCID
+/+ mice and transplantation of human
hepatocytes were performed as described previously [28]. All mice
were transplanted with hepatocytes from the same donor. Human
hepatocyte chimeric mice, in which liver cells were largely (.90%)
replaced with human hepatocytes, were used to reduce potential
influence by mouse-derived mRNA. The experiments were
performed in accordance with the guidelines of the local
committee for animal experiments at Hiroshima University.
A total of 15 chimeric mice were prepared and assigned to
four experimental groups. Group A contained four mice that
Figure 1. Change in HCV titers and human albumin levels in mouse serum. HCV RNA titers (upper panel) and human albumin levels (lower
panel) in chimeric mouse sera after inoculation are shown. The horizontal axis indicates weeks after inoculation. Mouse sera were collected every two
weeks after inoculation, and serum HCV RNA and human albumin levels were measured. Results were similar for all mice.
doi:10.1371/journal.pone.0023856.g001
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consisted of four uninfected mice that were administered IFN-a
(7,000 IU/g body weight) 6 h before sacrifice. Groups C and D
were inoculated via the mouse tail vein with human serum
containing 4610
5 copies of HCV particles, and Group D was
administered INF- a at the same time as Group B. After
inoculation, we collected mouse sera every two weeks and
analyzed serum HCV RNA levels by real time PCR. All seven
mice developed measurable viremia 4 weeks after inoculation.
The levels of the virus titer reached over 6 Log10 copies/ml 8
weeks after inoculation (Figure 1). Conversely, serum human
albumin levels remained more than 2610
6 ng/ml in each mouse
during 6 weeks after inoculation (Figure 1). Eight weeks after
inoculation, when serum HCV RNA levels had plateaued, IFN-a
(7,000 IU/g body weight) was administered to the four mice in
Group D as well as the four uninfected mice in Group B. Six
hours after IFN administration all 15 mice were sacrificed.
Infection, extraction of serum samples, and sacrifice were
performed under ether anesthesia as described previously [29–
31]. Human albumin levels in mouse serum were measured with
a Human Albumin enzyme-linked immunosorbent assay (ELISA)
Quantitation kit (Bethyl Laboratories Inc., Montgomery, TX)
according to the instructions provided by the manufacturer.
Serum samples obtained from mice were aliquoted and stored in
liquid nitrogen until use.
Analysis of HCV markers
For quantitative analysis of HCV RNA, 10 ml samples of mouse
serum were used. Total RNA was extracted using Sepa Gene RV-
R (Sanko Junyaku Co., Ltd., Tokyo, Japan) and dissolved with
8.8 mL of RNase free water and reverse transcribed (RT). RT
reactions were performed with 20 ml of the reaction mixtures,
containing random primer (Takara Bio Inc., Shiga, Japan), RT
buffer and M-MLV reverse transcriptase (ReverTra Ace,
TOYOBO Co., Osaka, Japan) according to the instructions
provided by the manufacturer. After the RT reaction, HCV RNA
was quantified by real-time PCR using the 7300 Real-Time PCR
System (Applied Biosystems, Foster City, CA). Amplification was
performed as described previously [29,30]. The lower detection
limit of this assay is 300 copies. For detection of small amounts of
HCV RNA, we also performed nested PCR. Amplification
conditions were as described previously [29,30].
Dissection of mouse livers and total RNA extraction from
human heptocytes in the mouse livers
All 15 chimeric mice were sacrificed by anesthesia with diethyl
ether. Human hepatocytes were finely dissected from mouse livers,
submerged in RNA laterH solution (Applied Biosystems), and stored
in liquid nitrogen. Total RNA was extracted using the Qiagen
RNeasy Mini Kit according to the manufacturer protocol (Qiagen
Inc., Valencia, CA). RNA quality was assessed using ultraviolet
Figure 2. Hierarchical clustering analysis of 181 genes associated with HCV infection. To analyze the influence of HCV infection on human
hepatocytes, clustering analysis on gene expression was performed between Group A (without HCV infection; 4 columns on the left side) and Group
C (with HCV infection; 3 columns on the right side). 157 genes were up-regulated following HCV infection, including interferon-stimulated genes
(ISGs) such as MX1 and genes in the CXCL and IFI families, and 24 genes were down-regulated, including ME1 and HMGCS1.
doi:10.1371/journal.pone.0023856.g002
Table 1. The top 20 genes up-regulated with HCV infection.
Probe set Unigene code Gene symbol Fold change P value
202237_at Hs.503911 NNMT 33.16 1.66E-03
205476_at Hs.75498 CCL20 30.23 1.59E-04
202859_x_at Hs.551925 IL8 30.16 4.42E-04
206336_at Hs.164021 CXCL6 25.52 1.86E-03
217546_at Hs.647370 MT1M 24.69 2.46E-04
212531_at Hs.204238 LCN2 24.17 9.19E-04
209894_at Hs.705413 LEPR 23.77 5.83E-04
204533_at Hs.632586 CXCL10 23.61 1.47E-05
213797_at Hs.17518 RSAD2 20.43 7.31E-05
204439_at Hs.715563 IFI44L 17.92 9.73E-04
213975_s_at Hs.706744 LYZ 15.22 1.10E-03
206643_at Hs.190783 HAL 14.88 3.98E-03
216598_s_at Hs.303649 CCL2 14.76 6.99E-03
235229_at Hs.332649 13.93 6.22E-04
205890_s_at Hs.714406 GABBR1///UBD 13.67 1.46E-03
33304_at Hs.459265 ISG20 13.58 5.61E-05
205569_at Hs.518448 LAMP3 10.96 3.58E-05
204470_at Hs.789 CXCL1 10.90 9.06E-03
208607_s_at Hs.632144 SAA1///SAA2 10.40 4.56E-03
205302_at Hs.642938 IGFBP1 9.55 1.10E-02
doi:10.1371/journal.pone.0023856.t001
Table 2. The top 20 genes down-regulated with HCV
infection.
Probe set Unigene code Gene symbol Fold change P value
207245_at Hs.575083 UGT2B17 20.04 2.15E-02
214043_at Hs.446083 PTPRD 6.81 2.57E-02
214416_at Hs.702961 6.36 3.51E-02
209220_at Hs.713537 GPC3 5.40 4.40E-02
238029_s_at Hs.504317 SLC16A14 4.90 1.16E-02
231594_at 4.59 1.87E-02
1556824_at Hs.702604 4.40 2.89E-02
232707_at Hs.567637 ISX 4.30 6.52E-03
205822_s_at Hs.397729 HMGCS1 4.23 1.95E-04
204058_at Hs.21160 ME1 4.06 2.15E-02
1555084_at 3.95 4.10E-02
215076_s_at Hs.443625 COL3A1 3.92 2.99E-02
209555_s_at Hs.120949 CD36 3.91 4.49E-02
221729_at Hs.445827 COL5A2 3.89 2.60E-02
217676_at Hs.696837 3.86 8.73E-03
233604_at Hs.280892 FLJ22763 3.82 2.44E-02
1563298_at Hs.352254 3.64 1.97E-02
224344_at Hs.497118 COX6A1 3.34 1.68E-02
237031_at Hs.146276 3.22 4.62E-04
216018_at Hs.534342 RNF5 3.19 3.13E-02
doi:10.1371/journal.pone.0023856.t002
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mington, DE) and agarose gel electrophoresis. Microarray analysis
was performed using the Affymetrix GeneChip Human Gene
U133Plus2.0 Array, which interrogates 38,500 genes across
54,675 distinct probes (Affymetrix, Santa Clara, CA). The
Affymetrix GeneChip Whole Transcript Sense Target Labeling
Assay Manual Version 4 was used for complementary DNA
(cDNA) generation, hybridization, and array processing. Briefly,
300 ng of total RNA underwent first-strand and second-strand
cDNA synthesis. Complementary RNA was generated and used to
produce sense-strand cDNA, which was fragmented and end-
labeled with biotin. Biotin-labeled cDNA was hybridized to the
Human Gene 1.0 ST Array for 16 hours at 45uC using the
GeneChip Hybridization Oven 640 (Affymetrix). Washing and
staining with streptavidin-phycoerythrin was performed using the
GeneChip Fluidics Station 450, and images were acquired using
the Affymetrix Scanner 3000 (Affymetrix).
Microarray Data Analysis and Hierarchical Clustering
Fluorescence intensities captured by the Affymetrix GeneChip
Scanner were converted to numerical values using the Affymetrix
GeneChip Operating Software, were log2 transformed, and were
standardized using quantile normalization with the Robust
Multiarray Analysis (RMA) algorithm [32,33]; this method
normalizes the distribution of probe intensities for all the gene
arrays in a given set.
Obtained gene expression profiles were analyzed using Gene-
Spring GX 10.0.2 software (Tomy Digital Biology, Tokyo, Japan).
Expression ratios were calculated and normalized per chip to the
50th percentile and finally normalized per gene to medians. We
worked on a pre-screened list of 32,885 probes obtained after
filtering the data for outliers, negative and positive controls, and on
the qualityflag Cy3 signals being ‘‘well above background.’’ To pass
this last flag, Cy3 net signals needed to be positive and significant,
withg(r)BGSubSignal greater than2.6 g(r) BG_SD.Todetermineif
there were genes differentially expressed among samples, we
performed two Welch’s t-tests (P,0.01) on this prescreened list of
genes: one without correction and one with Benjamini and
Hochberg’s correction. Complete linkage hierarchical clustering
analysis was applied using Euclidean distance, and differentially
expressed genes were annotated using the information from the
Gene Ontology Consortium. Global molecular networks and
comparisons of canonical pathways were generated using Ingenui-
ty
TM Pathway Analysis 8.6 (Ingenuity
TM Systems, CA, USA).
Real time PCR for analyzing the mRNA expression in the
human hepatocytes
Total RNA was extracted from the implanted human
hepatocytes in the mouse livers using RNeasy Mini Kit (Qiagen)
and reverse-transcribed using ReverTra Ace (TOYOBO, Osaka,
Japan) with random primer in accordance with the instructions
supplied by the manufacturer. The selected cDNA were quantified
by real-time PCR using the 7300 Real-Time PCR System
(Applied Biosystems, Foster City, CA), and the expression of
GAPDH served as a control. Amplification was performed in a
25 ml reaction mixture containing 12.5 ml SYBR Green PCR
Master Mix (Applied Biosystems), 5 pmol of forward primer,
5 pmol of reverse primer, and 1 ml of cDNA solution. After
incubation for 2 min at 50uC, the sample was denatured for
10 min at 95uC, followed by a PCR cycling program consisting of
40 cycles of 15 s at 95uC, 30 s at 55uC, and 60 s at 60uC.
Statistical analysis
Differences between groups were examined for statistical
significance using the Student’s t- test.
Table 3. The effect of HCV infection on biological functions by category.
Category P value Up-regulated genes in network Down-regulated genes in network
Number of
genes
Representative
genes
Number of
genes
Representative
genes
Organismal Injury and
Abnormalities
5.90E-16–3.66E-03 27 CXCL1, CXCL6, CXCL9, CXCL10, IFIT1,
IFIT3, MX1, etc.
1 SERPINI1
Cancer 1.81E-13–5.73E-03 54 BIRC3, CXCL9, CXCL10, GBP1, IFIT3,
IGFBP1, ISG20, MAP3K8, etc.
4 CD36, COL3A1, GPC3, RNF5
Inflammatory Response 9.31E-13–5.89E-03 39 APOBEC3G, CCL2, CXCL9, CXCL10, IL8,
MX1, STAT1, TRIM22, etc
2 CD36, COL3A1
Cell-To-Cell Signaling and
Interaction
4.95E-10–4.99E-03 30 CCL2, CD74, CXCL1, CXCL2, CXCL9,
ICAM1, IL8, NRG1, STAT1, etc.
3 CD36, SERPINI1, GPC3
Hematological System
Development and Function
4.95E-10–5.95E-03 36 CCL2, CCL20, CXCL9, CXCL10, IL8,
IL1RN, TNFAIP3, etc
1 CD36
Immune Cell Trafficking 4.95E-10–5.73E-03 26 CCL2, CCL20, CTSS, CXCL6, CXCL9,
CXCL10, MDK, NEDD9, etc.
1 CD36
Infection Mechanism 5.03E-10–3.66E-03 16 CCL2, CXCL9, CXCL10, DDX58, IFIT1,
IL8, ISG20, MX1, RSAD2, STAT1, etc.
0
Infectious Disease 5.03E-10–5.46E-03 26 APOBEC3G, CXCL9, CXCL10, DDX58,
MT1X, STAT1, TNFAIP3, etc
2 CD36, HMGCS1
Reproductive System
Disease
6.43E-10–1.37E-03 42 CCL2, CXCL1, CXCL2, IFIT1, IGFBP1,
KLF4, MAP3K8, NEDD9, SPP1, etc.
1 RNF5
Cellular Movement 6.64E-10–5.91E-03 31 IGFBP1, IL8, KLF4, MDK, NEDD9,
NRG1, RARRES1, SOD2, TNFAIP8, etc
2 CD36, RNF5
doi:10.1371/journal.pone.0023856.t003
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Change of gene expression with HCV infection
To analyze the effect of HCV infection on gene expression in
human hepatocytes, we compared the gene expression profiles
between Group A (without HCV infection) and Group C (with
HCV infection). Among the 2,519 genes that remained
significant after screening by Welch’s t-test, more than 3.0-fold
expression changes between groups were observed in 181 genes.
157 of these 181 genes were up-regulated following HCV
infection, and the other 24 were down-regulated. Cluster
analysis of the 181 genes is shown in Figure 2, and the top 20
up-/down-regulated genes by HCV infection are listed in
Tables 1 and 2, respectively.
It is well known that chronic HCV infection triggers multiple
biological responses. To analyze biological significance and
regulatory pathways involved in the changes observed, we
performed network analysis with the 181 genes using Ingenuity
TM
Pathway Analysis (IPA). As shown in Table 3, most of the 181
genes (e.g. CXCL9, CXCL10, IFIT3 and Mx1, which are well
known interferon-stimulated genes (ISGs)) belonged to categories
such as Organismal Injury and Abnormalities, Inflammatory
Response, and Cell-To-Cell Signaling and Interaction. Through
canonical pathway analysis of the 181 genes using Ingenuity
Pathways Analysis, 10 canonical pathways significantly affected by
HCV infection were identified, with interferon signaling as the
most significant (Figure 3). These results indicate that the intra-
hepatic innate immune response was strongly activated by HCV
infection in human hepatocytes.
Change of gene expression with interferon treatment
To analyze the direct effects of IFN in human hepatocytes, we
compared gene expression profiles between Group A (without IFN
treatment) and Group B (with IFN treatment). Out of the 218
genes that remained significant after screening by Welch’s t-tests
and Benjamini-Hochberg correction for multiple testing, 158 had
a greater than 3.0-fold change between groups. 152 of the 158
genes were up-regulated following IFN administration, and the
other 6 were down-regulated. Cluster analysis of the 158 selected
genes is shown in Figure 4. The top 35 up-regulated genes (.10.0-
fold changes), which include many well-known ISGs (e.g.,
members of the CXCL and IFI families), and the 6 down-regulated
genes are listed in Tables 4 and 5, respectively.
The effect of HCV infection on IFN response
To analyze the effect of HCV infection on IFN response, we
focused on the 152 genes that were up-regulated following IFN
administration and compared gene expression ratios between
Groups A and B (gene expression changes by IFN without HCV
infection) and between Groups C and D (gene expression changes
by IFN with HCV infection). In 69.7% (106/152) of the IFN-
induced genes, IFN responsiveness was significantly reduced
following HCV infection (Figure 5). The top 20 genes are shown
in Table 6. Although viral titers differed among mice, we found no
correlation between IFN responsiveness and HCV RNA titer. We
performed pathway analysis to identify significant associations with
canonical pathways, and the top 5 associated pathways are shown
in Table 7. IFN responsiveness was significantly reduced following
HCV infection in several canonical pathways, and the IFN
Figure 3. The effects of HCV infection on canonical pathways. To analyze the effects of HCV infection on canonical pathways, pathway
analysis was performed using the 181 genes identified to be significantly up- or down-regulated following HCV infection. The IFN signaling pathway
was the most significantly affected by HCV infection. Statistical analysis was performed using Fisher’s exact test.
doi:10.1371/journal.pone.0023856.g003
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the effects of HCV infection and/or IFN treatment on gene
expression, signal intensities of genes involved in the IFN and
JAK-STAT signaling pathways were analyzed. As shown in
Figure 6A, among 28 representative genes in the IFN signaling
pathway, signal intensities of 22 genes could be analyzed through
cDNA microarray analysis. In all genes except IFNAR1, expression
was up-regulated following HCV infection, whereas IFN respon-
siveness was suppressed as a result of HCV infection (Figure 6B).
16 out of 22 genes in the JAK-STAT signal pathway could be
analyzed via cDNA microarray analysis (Figure 6C), and 12 of the
16 genes were up-regulated following HCV infection, whereas IFN
responsiveness was suppressed in 9 genes (Figure 6D).
On the other hand, only 33 genes (21.7%), including several
ISGs, such as GBP1, GBP4 and IFIT3, remained responsive to IFN
in the presence of HCV and were expressed more than 3.0-fold
higher in Group D compared to Group C (Table 8). Pathway
analysis indicated that these 33 genes were significantly associated
with Antimicrobial Response and Inflammatory Response
(P=5.22610
210 , 1.95610
22). Changes in mRNA expression
for 29 down-regulated genes, including ISG20, WARS, Mx1,
CXCL10, IFNGR1 and IFITM1 were verified by real time PCR
(data not shown).
Discussion
We previously developed a human hepatocyte chimeric mouse
model that can be chronically infected with hepatitis B and C
viruses [29–31]. This mouse model has enabled us to analyze the
effect of viral infection and the response to medication under
immunodeficient conditions. Microarray analyses using the
human hepatocyte chimeric mouse model with HCV infection
have recently been reported, and HCV infection was found to
affect expression of genes related to innate antiviral immune
response, lipid metabolism and apoptosis via ER stress [34,35].
Whereas these reports were concerned especially with host specific
responses to HCV infection, no studies addressing viral modula-
tion of the IFN response have been reported, even though such
studies might be important for understanding viral evasion
mechanisms in response to IFN therapy and for improving
therapy effectiveness for chronic hepatitis C. Therefore, in this
study we performed cDNA microarray analysis using a human
hepatocyte chimeric mouse model and obtained gene expression
profiles to investigate direct influences of HCV infection on IFN
responses in human hepatocytes.
First, we evaluated host response to HCV infection in human
hepatocytes by comparing profiles between groups A (without
HCV infection) and C (with HCV infection). 181 genes were
significantly up- or down-regulated following HCV infection.
Canonical pathway analysis revealed that genes involved in IFN
Figure 4. Hierarchical clustering analysis of 158 genes associated with IFN treatment. To analyze the effects of IFN in human hepatocytes,
clustering analysis was performed between Group A (without IFN treatment; 4 columns on the left side) and Group B (with IFN treatment; 4 columns
on the right side). 152 genes were up-regulated, and 6 genes were down-regulated following IFN treatment. Several well-known interferon-
stimulated genes (ISGs), including CXCL9, Mx1, ISG20 and OASL, were among the up-regulated genes.
doi:10.1371/journal.pone.0023856.g004
Table 4. The top 35 genes up-regulated with IFN treatment.
Probe set Unigene code Gene symbol
Fold
change P values
211122_s_at Hs.632592 CXCL11 482.47 1.30E-06
203915_at Hs.77367 CXCL9 216.26 1.35E-07
242625_at Hs.17518 RSAD2 101.24 1.26E-05
202237_at Hs.503911 NNMT 86.80 6.52E-06
217502_at Hs.437609 IFIT2 75.05 1.73E-06
204533_at Hs.632586 CXCL10 67.43 2.72E-07
217546_at Hs.647370 MT1M 46.69 1.12E-04
235175_at Hs.409925 GBP4 44.94 1.03E-06
204205_at Hs.660143 APOBEC3G 43.39 5.55E-06
204747_at Hs.714337 IFIT3 32.73 1.17E-06
218943_s_at Hs.190622 DDX58 32.19 1.44E-04
33304_at Hs.459265 ISG20 31.97 3.94E-05
202269_x_at Hs.62661 GBP1 31.73 5.30E-06
210797_s_at Hs.118633 OASL 31.59 9.21E-06
200629_at Hs.497599 WARS 29.65 2.28E-04
206332_s_at Hs.380250 IFI16 26.37 3.80E-05
210302_s_at Hs.584852 MAB21L2 24.31 5.31E-07
228531_at Hs.65641 SAMD9 18.65 1.45E-05
223298_s_at Hs.487933 NT5C3 17.48 6.65E-06
219863_at Hs.26663 HERC5 17.02 2.29E-05
225710_at Hs.173030 GNB4 16.98 3.30E-05
219684_at Hs.43388 RTP4 16.38 2.55E-05
212657_s_at Hs.81134 IL1RN 15.18 1.33E-06
219352_at Hs.529317 HERC6 14.86 1.31E-04
226702_at Hs.7155 CMPK2 12.50 1.86E-05
205842_s_at Hs.656213 JAK2 12.49 6.16E-05
230036_at Hs.489118 SAMD9L 11.98 7.84E-05
214995_s_at Hs.660143 APOBEC3F///
APOBEC3G
11.62 1.58E-04
823_at Hs.531668 CX3CL1 11.15 1.07E-04
203153_at Hs.20315 IFIT1 10.84 5.93E-06
225076_s_at Hs.371794 ZNFX1 10.40 1.38E-06
213069_at Hs.477420 HEG1 10.37 3.52E-05
205483_s_at Hs.458485 ISG15 10.34 1.29E-05
235276_at Hs.546467 EPSTI1 10.21 2.10E-04
219209_at Hs.163173 IFIH1 10.05 4.06E-05
doi:10.1371/journal.pone.0023856.t004
Table 5. The top 6 genes down-regulated with IFN treatment.
Probe set
Unigene
code Gene symbol
Fold
change P value
206211_at SELE 5.83 6.11E-05
224875_at C5orf24 5.46 1.11E-04
227256_at Hs.183817 USP31 3.94 7.27E-05
220070_at Hs.145717 JMJD5 3.87 5.04E-05
1552482_at Hs.471162 RAPH1 3.31 1.73E-04
226587_at Hs.592473 SNRPN 3.17 6.13E-05
doi:10.1371/journal.pone.0023856.t005
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infection (Figure 3). These findings are mostly consistent with
previous studies [36,37]. On the other hand, while no genes
involved in lipid metabolism showed any significant induction by
HCV infection in this study, Walters et al. reported that HCV-
infected chimeric mice exhibited host-specific induction in the
expression of lipid metabolism genes [35]. However, we used
hepatocytes from a single donor, whereas Walters et al. used
hepatocytes from multiple donors, so our results are not necessarily
inconsistent with their findings that HCV infection causes
induction of lipid metabolism genes in a host-specific manner.
Although several cDNA microarray analyses have also been
performed using human liver tissues obtained after hepatic
resection, the largest difference between human and chimeric
mouse livers is the presence or absence of human lymphocytes.
According to the previous report using human liver tissues, genes
involved in the innate immune response, as well as cell cycle,
growth and communication, were up-regulated by HCV infection
[38]. In the present study using SCID-derived mice, genes
involved in immune response (e.g. OAS2, Mx1, IFI27 and IFI44L),
cell cycle and growth (e.g. HERC5) and cell communication (e.g.
HLA-B) were similarly up-regulated by HCV infection. However,
Apolipoprotein L, Cold autoinflammatory syndrome 1, CD97 antigen, and
HLA-DQ, which are mainly expressed in lymphocytes, were not
observed to be up-regulated by HCV infection in the chimeric
mice. These results demonstrate that the chimeric mouse model
accurately reflects intracellular responses to HCV infection
without the lymphocytic immune response.
To verify the microarray results, expression data were
compared with previously published microarray data on the
GEO website (http://www.ncbi.nlm.nih.gov/geo/). Previously
published microarray data showed up-regulation of IGFBP7,
IFI27, HLA-B, and CD74 in HCV-infected liver tissues compared
to non-infected liver tissues (fold changes were 2.1, 2.2, 2.1 and
2.3, respectively) [39]. Likewise, we found that IFI27, HLA-B, and
CD74 were up-regulated following HCV infection (fold changes
were 3.6, 3.3, and 6.6, respectively). These three genes are
associated with MHC class I activity, suggesting that intra-cellular
immunity in human hepatocytes was activated following HCV
infection both in human subjects and in chimeric mouse livers.
Metallothionein 1G (MT1G) expression was also found to be up-
regulated by HCV infection in both the current and published
studies [39,40]. Although metallothionein isoforms are associated
with collagen deposition [41], members of the metallothionein
family may be up-regulated and induce liver fibrosis in response to
HCV infection.
In this study, genes associated with Organismal Injury and
Abnormalities were found to be up-regulated in response HCV
infection (Table 3), and some genes in this category, such as
CXCL9, CXCL10 and IFIT3, maintained high IFN responsiveness
under HCV infection (Table 8). These results suggest that
protective responses to fibrosis or hepatic injury were activated
at the start of HCV infection and remained activated until
complete eradication of HCV from hepatocytes was achieved.
Secondly, we compared gene expression profiles between
groups A (without IFN treatment) and B (with IFN treatment) to
evaluate IFN response without HCV infection. IFN-a stimulates
the intracellular IFN-signaling cascade after binding to the IFN-a
receptor and mediates the transcriptional activation of IFN-
stimulated genes [42–47]. More than 3.0-fold up-regulation was
observed 6hrs after IFN treatment in 152 genes. Known ISGs such
as those in the CXCL family (CXCL9, CXCL10 and CXCL11), the
IFIT family (IFIT2 and IFIT3) and the APOBEC family
(APOBEC3G) were included among the top 20 genes up-regulated
following IFN treatment (Table 4). The APOBEC family is well
known to have anti-viral effects by inducing genomic hypermuta-
tion in human immunodeficiency virus and hepatitis B virus [48–
57]. APOBEC3G expression has been reported to be elevated in
patients infected with HCV [58], although it is not clear whether
APOBEC3G can block HCV replication. On the other hand,
CXCL9 and IFIT3 were reported to relate to liver fibrosis in
chronic hepatitis C patients. Serum CXCL9 concentrations
correlated with the levels of fibrosis in chronic hepatitis C patients,
and CXCL9 has been shown to exert anti-fibrotic effects in vitro and
in vivo [59]. IFIT3 expression is also reportedly up-regulated in the
transition from mild to moderate fibrosis [60]. The results of this
study suggest that IFN treatment might lead not only to HCV
eradication but also help to prevent and repair liver fibrosis by
inducing these key molecules.
We focused on the 152 genes up-regulated (. 3.0 fold) as a
result of IFN administration and evaluated the effect of HCV
infection on IFN response among these genes. As shown in
Table 8, although several ISGs still showed high response to IFN
Figure 5. Hierarchical clustering analysis of 152 genes associated with IFN administration with or without HCV infection. To analyze
the effect of HCV infection on IFN response, gene expression ratios between Groups A and B (gene expression changes by IFN without HCV infection)
and those between Groups C and D (gene expression changes by IFN with HCV infection) were compared in the 152 IFN-induced genes. 69.7% of the
selected genes showed reduced IFN responsiveness following HCV infection.
doi:10.1371/journal.pone.0023856.g005
Table 6. The top 20 genes in which IFN-induced
up-regulation is inhibited following HCV infection.
Probe Set ID Gene symbol Fold change P value
HCV
infection (-)
HCV infection
(+)
235175_at GBP4 44.94 5.50 2.93E-07
231577_s_at GBP1 24.60 4.89 6.15E-07
218943_s_at DDX58 32.19 5.56 1.26E-05
226702_at CMPK2 12.50 2.13 2.35E-05
225973_at TAP2 7.07 2.84 3.31E-05
229450_at IFIT3 20.66 2.74 6.37E-05
217739_s_at NAMPT 5.91 1.95 6.51E-05
213797_at RSAD2 69.70 4.50 7.01E-05
210797_s_at OASL 31.59 3.53 1.02E-04
218508_at DCP1A 3.56 1.65 1.36E-04
228531_at SAMD9 18.65 5.87 1.45E-04
204804_at TRIM21 5.37 2.69 1.47E-04
219209_at IFIH1 10.05 4.69 1.67E-04
219684_at RTP4 16.38 2.55 1.98E-04
239186_at MGC39372 7.61 2.57 2.27E-04
219211_at USP18 8.72 3.74 2.40E-04
225076_s_at ZNFX1 10.40 2.91 2.91E-04
204698_at ISG20 31.29 3.33 3.00E-04
223192_at SLC25A28 5.05 2.20 3.25E-04
228439_at BATF2 4.59 1.83 3.28E-04
doi:10.1371/journal.pone.0023856.t006
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Signaling pathway became unresponsive (Table 6). Reduction in
IFN responsiveness was also observed for STAT1 (4.27 fold in the
absence of HCV to 2.29 fold in the presence of HCV,
P=4.04610
24), as well as 5 of 7 genes downstream of STAT1
(IFIT1, IFIT3, IRF1, MX1, and TAP1). As shown in Figure 3, IFN
Table 7. The top 5 canonical pathways associated with the 106 genes in which IFN response is suppressed by HCV infection.
Category P value Ratio Associated genes
Interferon Signaling 4.41E-11 7/30 genes IFIT1, IFIT3, IFNGR1, IRF1, MX1, STAT1,
TAP1
Type I Diabetes Mellitus Signaling 1.08E-04 5/119 genes HLA-E, IFNGR1, IRF1, RIPK1, STAT1
Antigen Presentation Pathway 5.29E-04 3/39 genes HLA-E, TAP1, TAP2
Primary Immunodeficiency Signaling 1.64E-03 3/63 genes BLNK, TAP1, TAP2
Activation of IRF by Cytosolic Pattern
Recognition Receptors
2.95E-03 3/73 genes ISG15, RIPK1, STAT1
doi:10.1371/journal.pone.0023856.t007
Figure 6. Changes in expression of genes in the IFN and JAK-STAT signaling pathways under HCV infection and/or IFN
administration. A) An overview of the IFN signaling pathway consisting of 26 representative genes is shown. Genes illustrated as gray shapes were
not included in this study. B) Relative expression levels of genes with/without HCV infection and/or IFN administration were plotted (closed dots: with
HCV infection; open dots: without HCV infection) using microarray data. The slopes of the dashed and solid lines represent IFN responsiveness with
and without HCV infection, respectively. In 21 of the 22 examined genes in the IFN signaling pathway, signal intensities increased and IFN
responsiveness was repressed following HCV infection. Student’s t-test was used for statistical analysis. C) An overview of the JAK-STAT signaling
pathway consisting of 22 representative gene products is shown. Genes illustrated as gray shapes were not included in this study. D) Relative
expression levels of genes with/without HCV infection and/or IFN administration were plotted using microarray data (closed dots: with HCV infection;
open dots: without HCV infection). Signal intensities increased following HCV infection in 16 of 22 genes in the JAK-STAT signaling pathway, and IFN
response was suppressed in 9 genes. Statistical analysis was performed using Student’s t-test.
doi:10.1371/journal.pone.0023856.g006
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expression of STAT1 was more than 3.0 fold up-regulated by
HCV infection (data not shown). STAT1 expression was highest in
mice with both HCV infection and IFN treatment, but
downstream genes such as MX1, IFIT1 and IFIT3 showed
reduced IFN response. Sarasin-Filipowicz et al. reported that
IFN-induced STAT1 phosphorylation was stronger in rapid
responders than in non-rapid responders [61]. Reduced induction
of genes downstream of STAT1 by IFN under HCV infection
might reflect reduced phosphorylation of STAT1, although we did
not quantify STAT1 phosphorylation in this study.
Recently, an IL-28B genetic polymorphism strongly associated
with response to IFN-a plus ribavirin combination therapy [12], as
well as with hepatic ISG expression [62], was identified. Further
studies using chimeric mice transplanted with hepatocytes carrying
different genotypes of candidate genes such as IL-28B will be
important in order to elucidate possible mechanisms underlying
host-specific responses.
In conclusion, we performed cDNA microarray analysis using
HCV-infected human hepatocyte chimeric mice, which allowed
us to analyze the direct effects of IFN treatment and HCV
infection without the confounding effects of the lymphocytic
immunological response. These results might provide molecular
insights into possible mechanisms used by HCV to evade IFN-
induced immune responses, as well as suggest novel therapeutic
targets and a potential new indication for interferon therapy.
Further analysis of the genes identified in our study would be
worthwhile in order to improve efficacy of the therapy for chronic
hepatitis C.
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Table 8. The 33 genes that remained more than 3-fold up-regulated following IFN treatment in HCV-infected mice.
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206332_s_at IFI16 Nucleus transcription regulator
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223298_s_at NT5C3 Cytoplasm phosphatase
205660_at OASL unknown enzyme
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